Multicenter Evaluation of Ceftolozane/Tazobactam for Serious Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa

Jose M. Munita, Samuel L. Aitken, William R. Miller, Federico Perez, Rossana Rosa, Luis A. Shimose, Paola Lichtenberger, Lilian Abbo, Rupali Jain, Masayuki Nigo, Audrey Wanger, Rafael Araos, Truc T. Tran, Javier Adachi, Robert Rakita, Samuel Shelburne, Robert A. Bonomo, Cesar A. Arias

Research output: Contribution to journalArticle

65 Scopus citations

Abstract

A multicenter, retrospective study of patients infected with carbapenem-resistant Pseudomonas aeruginosa who were treated with ceftolozane/tazobactam was performed. Among 35 patients, pneumonia was the most common indication and treatment was successful in 26 (74%). Treatment failure was observed in all cases where isolates demonstrated ceftolozane-tazobactam minimum inhibitory concentrations ≥8 μg/mL.

Original languageEnglish (US)
Pages (from-to)158-161
Number of pages4
JournalClinical Infectious Diseases
Volume65
Issue number1
DOIs
StatePublished - Jul 1 2017

Keywords

  • carbapenem resistant
  • Ceftolozane
  • multidrug resistant
  • P. aeruginosa

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Multicenter Evaluation of Ceftolozane/Tazobactam for Serious Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa'. Together they form a unique fingerprint.

  • Cite this

    Munita, J. M., Aitken, S. L., Miller, W. R., Perez, F., Rosa, R., Shimose, L. A., Lichtenberger, P., Abbo, L., Jain, R., Nigo, M., Wanger, A., Araos, R., Tran, T. T., Adachi, J., Rakita, R., Shelburne, S., Bonomo, R. A., & Arias, C. A. (2017). Multicenter Evaluation of Ceftolozane/Tazobactam for Serious Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa. Clinical Infectious Diseases, 65(1), 158-161. https://doi.org/10.1093/cid/cix014